SWM
CMMB

Spire Wealth Management’s Chemomab Therapeutics CMMB Stock Holding History

Spire Wealth Management’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-125
Closed -$6K – 2932
2021
Q3 		$6K Hold
125
– – ﹤0.01% 2229
2021
Q2 		$10K Buy
+125
New +$12.2K ﹤0.01% 2104

Other funds holding CMMB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Spire Wealth Management's CMMB Position: Q4 2021 in Review

Spire Wealth Management sold out of Chemomab Therapeutics (CMMB) in Q4 2021, closing a stake of 125 shares — an estimated $6K sold.

Spire Wealth Management first reported a position in CMMB in Q2 2021 and held it in 2 quarters. The position peaked at $10K in Q2 2021. 14 funds tracked by Wall St. Rank hold CMMB as of Q4 2021.

  • Spire Wealth Management reported no remaining Chemomab Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Spire Wealth Management sold 125 Chemomab Therapeutics shares in Q4 2021, an estimated $6K.
  • Spire Wealth Management first reported a position in Chemomab Therapeutics in Q2 2021 and held it in 2 quarters.
  • Spire Wealth Management's Chemomab Therapeutics position peaked at $10K in Q2 2021.
  • 14 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q4 2021.

Based on Spire Wealth Management's 13F filing for Q4 2021, filed 14 Jan 2022.